Skip to content
← Layoff Watch

Vistagen Therapeutics, Inc.

Number not stated

SEC filingAnnounced

Vistagen Therapeutics, Inc. discloses a restructuring plan in an SEC filing

Industry
Biotech
Filed with the SEC
October 30, 2026
Share of workforce
31%
Whose workers
Scope not stated
In the report for
October 31, 2026

What happened

Vistagen Therapeutics, Inc. disclosed a restructuring plan in an SEC filing without stating how many jobs it affects. The filing puts the reduction at about 31% of its workforce.

Sources

  • SEC EDGAR · SEC filing · Oct 30, 2026

    (the “ Company ”) implemented a Board-approved reduction in workforce by approximately 31%, retaining core clinical, regulatory, technical, and corporate capabilities required for U.S. registration-directed Phase 3 development of fasedienol, its lead clinical-stage product candidate for treatment of social anxiety disorder, as well as potential future development of its lead Phase 2 product candidates, itruvone for major depressive disorder and refisolone for menopausal hot flashes.
    Read the source

This reports what the source says. It says nothing about any individual's immigration status.